SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor.

COVID-19 CelCradle Vero cells animal component-free inactivated vaccine packed-bed scalable bioreactor severe acute respiratory syndrome coronavirus 2 whole virus vaccine

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
29 Jun 2021
Historique:
received: 19 04 2021
revised: 11 06 2021
accepted: 15 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. This study aimed to establish SARS-CoV-2 production in the scalable packed-bed CelCradle

Identifiants

pubmed: 34209694
pii: vaccines9070706
doi: 10.3390/vaccines9070706
pmc: PMC8310283
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Candys Foundation
ID : none
Organisme : Danish Agency for Science and Higher Education
ID : none
Organisme : Kræftens Bekæmpelse
ID : none
Organisme : Hvidovre Hospital Research Foundation
ID : none
Organisme : Danmarks Frie Forskningsfond
ID : none
Organisme : Medical Sciences
ID : none
Organisme : Innovationsfonden
ID : none
Organisme : Læge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat
ID : none
Organisme : Mauritzen La Fontaine Fonden
ID : none
Organisme : Novo Nordisk Fonden
ID : none
Organisme : Region Hovedstaden
ID : none
Organisme : Toyota Foundation
ID : none
Organisme : Weimann Foundation
ID : none

Références

Expert Rev Vaccines. 2009 May;8(5):607-18
pubmed: 19397417
Vaccines (Basel). 2021 Apr 01;9(4):
pubmed: 33916180
Biotechnol J. 2021 Jan;16(1):e2000020
pubmed: 32971565
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Wkly Epidemiol Rec. 2015 Feb 27;90(9):69-87
pubmed: 25726573
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Wkly Epidemiol Rec. 2011 Jun 10;86(24):241-56
pubmed: 21661276
Lancet Infect Dis. 2021 Jan;21(1):39-51
pubmed: 33069281
Viruses. 2019 Jun 04;11(6):
pubmed: 31167384
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Methods Mol Biol. 2019;1911:85-91
pubmed: 30593619
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Lancet. 2020 Dec 12;396(10266):1861
pubmed: 33308453
Biologicals. 2007 Oct;35(4):221-6
pubmed: 17400474
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Nat Commun. 2020 Nov 26;11(1):6013
pubmed: 33243994
Hum Gene Ther. 2015 Aug;26(8):560-71
pubmed: 26176404
Cytotechnology. 2006 Jul;51(3):183-92
pubmed: 19002888
Nat Rev Microbiol. 2011 Oct 03;9(12):889-93
pubmed: 21963800
J Clin Med. 2021 Jan 24;10(3):
pubmed: 33498861
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
Hepatology. 2019 Sep;70(3):771-787
pubmed: 30964552
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0009721
pubmed: 33903110
Vaccines (Basel). 2020 Oct 03;8(4):
pubmed: 33022950
Lancet Infect Dis. 2021 May;21(5):637-646
pubmed: 33485468
Appl Biochem Biotechnol. 1991 Jul;30(1):29-41
pubmed: 1952924
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0268020
pubmed: 34097489
Vaccine. 2014 May 19;32(24):2782-8
pubmed: 24583004
Viruses. 2021 Jan 14;13(1):
pubmed: 33466921
Emerg Microbes Infect. 2020 Dec;9(1):837-842
pubmed: 32301390
iScience. 2021 Apr 23;24(4):102298
pubmed: 33723528
Vaccine. 2019 Nov 8;37(47):7003-7010
pubmed: 31047676
Cell. 2020 Aug 6;182(3):713-721.e9
pubmed: 32778225
PLoS One. 2019 Aug 12;14(8):e0220803
pubmed: 31404117
Vaccine. 2018 May 24;36(22):3124-3133
pubmed: 29433897
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Hum Vaccin Immunother. 2016 Sep;12(9):2351-6
pubmed: 27269431
Sci Rep. 2021 Jul 16;11(1):14571
pubmed: 34272426
Expert Rev Vaccines. 2016 Dec;15(12):1535-1544
pubmed: 27267297
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
Biotechnol Prog. 2003 Jan-Feb;19(1):202-8
pubmed: 12573026
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Cytotechnology. 2006 Nov;52(3):199-207
pubmed: 19002878
J Biotechnol. 2005 Aug 4;118(2):135-47
pubmed: 15951042
Appl Microbiol Biotechnol. 2019 Apr;103(7):3025-3035
pubmed: 30796494
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
J Virol. 2010 May;84(10):5277-93
pubmed: 20200247

Auteurs

Anna Offersgaard (A)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Carlos Rene Duarte Hernandez (CR)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Anne Finne Pihl (AF)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Rui Costa (R)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Nandini Prabhakar Venkatesan (NP)

Esco Aster Pte Ltd., Singapore 486 777, Singapore.

Xiangliang Lin (X)

Esco Aster Pte Ltd., Singapore 486 777, Singapore.

Long Van Pham (L)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Shan Feng (S)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Ulrik Fahnøe (U)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Troels Kasper Høyer Scheel (TKH)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Santseharay Ramirez (S)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Udo Reichl (U)

Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, Germany.

Jens Bukh (J)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Yvonne Genzel (Y)

Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, Germany.

Judith Margarete Gottwein (JM)

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, 2650 Hvidovre, Denmark.
Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

Classifications MeSH